Clinical trials: Mask
Neurotrophic Keratopathy
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
- Trial name
- NCT05555589
- Testing
- RGN-259
- Where
- 36 sites in United States, Italy and 2 more
- Volunteers
- 70 people
- Sponsor
- ReGenTree, LLC
Primary Open Angle Glaucoma, Open Angle Glaucoma
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
The goal of this clinical trial is to show non-inferiority of the MIMS® device/procedure with Mitomycin-C, in terms of its surgical success rate, compared to trabeculectomy with Mitomycin-C in subjects diagnosed with primary open…
- Trial name
- NCT06313749
- Testing
- Minimally Invasive Micro Sclerostomy Device
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Sanoculis Ltd
Macular Degeneration, Choroidal Neovascularization
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with…
- Trial name
- NCT00433017
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 12 sites in Austria, Belgium and 10 more
- Volunteers
- 255 people
- Sponsor
- Novartis
Dry Eye Disease
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
To assess the safety, tolerability and efficacy of a single dose of OTX-CSI, a sustained release cyclosporine drug product, in subjects with dry eye disease.
- Trial name
- NCT04362670
- Testing
- OTX-CSI
- Where
- 15 sites in United States
- Volunteers
- 153 people
- Sponsor
- Ocular Therapeutix, Inc.
Primary Open-angle Glaucoma, Ocular Hypertension
Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
This Phase 1/2a study is intended to assess the safety, tolerability, and effects on intraocular pressure of two dose levels and two dose frequencies of LX7101 when administered topically in the eyes of patients diagnosed with…
- Trial name
- NCT01528111
- Testing
- LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- Lexicon Pharmaceuticals
Presbyopia
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia
This is a Multicenter, Randomized, Double-Masked Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia.
- Trial name
- NCT05124275
- Testing
- Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3
- Where
- 10 sites in United States
- Volunteers
- 123 people
- Sponsor
- Glaukos Corporation
Age-related Macular Degeneration
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
A randomized, double-masked, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy.
- Trial name
- ReCLAIM-2 (NCT03891875)
- Testing
- Subcutaneous elamipretide through the elamipretide delivery system
- Where
- 37 sites in United States
- Volunteers
- 176 people
- Sponsor
- Stealth BioTherapeutics Inc.
Neovascular Age Related Macular Degeneration(nAMD)
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- ASCEND (NCT07798375)
- Testing
- VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration
- Volunteers
- 244 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Noninvasive Ventilation, Respiratory Insufficiency
A Feasibility Study Evaluating the Use of a Non-invasive Ventilation Mask
Evaluate the clinicians assessment of the use of an oro-nasal mask during non-invasive ventilation (non-intubated) with a feasibility study.
- Trial name
- mask (NCT02383719)
- Testing
- Oro-nasal Mask
- Volunteers
- 18 people
- Sponsor
- Convergent Engineering, Inc.
Dry Eye
Study of EBI-005 in Dry Eye Disease (DED)
This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye…
- Trial name
- EBI-005 (NCT02405039)
- Testing
- EBI-005
- Where
- 12 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eleven Biotherapeutics
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Dry Eye
A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period
The objective of this study is to assess the safety and efficacy of doxycycline 0.025% (ALTY-0501) ophthalmic solution for the treatment of dry eye using the Controlled Adverse Environment (CAE) Model.
- Trial name
- NCT00439400
- Testing
- doxycycline
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Alacrity Biosciences, Inc.
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
- Trial name
- NCT03310580
- Testing
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 40 sites in United States
- Volunteers
- 42 people
- Sponsor
- Aerie Pharmaceuticals
Age-Related Maculopathy
Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)
The primary purpose of this study is to determine if injections of rhuFab V2 into the eye in combination with verteporfin photodynamic therapy (PDT) is a safe and efficacious treatment for patients with age-related macular…
- Trial name
- NCT00056823
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 168 people
- Sponsor
- Genentech, Inc.
Diabetic Macular Edema
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
Three hundred and twenty-four (324) eligible adult subjects with diabetes mellitus with central DME involvement to be randomized 1:1 to intravitreal treatment with MYL-1701P or Eylea®.
- Trial name
- DME (NCT03610646)
- Testing
- MYL-1701P, Eylea
- Where
- 73 sites in United States, Czechia and 7 more
- Volunteers
- 355 people
- Sponsor
- Mylan Pharmaceuticals Inc
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Trial name
- NCT06864988
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 94 sites in United States, Canada
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Non-Infectious Uveitis
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye.
- Trial name
- FAI (NCT01694186)
- Testing
- FAI insert
- Where
- 34 sites in United States, Germany and 4 more
- Volunteers
- 129 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Myopia
Myopia Control With Novel Eye Drops
Myopia currently affects 30% of the world and by 2050, almost 50% of the world will be myopic based on conservative estimates.1 In 2050, this will equate to almost 5 billion people with myopia, and those with high myopia will…
- Trial name
- NCT04301323
- Testing
- BHVI1 eye drops, BHVI2 eye drops, BHVI3 eye drops
- Where
- Vietnam
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Hai Yen Eye Care
Obstructive Sleep Apnea
Evaluation of a Full Face Mask for the Treatment of Obstructive Sleep Apnea (OSA) in NZ
This investigation is designed to evaluate the performance (leak and comfort) as well as participant's overall acceptance of the investigative full face mask amongst OSA participants.
- Trial name
- NCT02540603
- Testing
- F&P Jupiter Full Face Mask
- Volunteers
- 15 people
- Sponsor
- Fisher and Paykel Healthcare
Diabetic Macular Edema (DME)
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in…
- Trial name
- NCT04857996
- Testing
- UBX1325
- Where
- 22 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Unity Biotechnology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.